WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010146058) BACE1 INHIBITORY ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/146058    International Application No.:    PCT/EP2010/058403
Publication Date: 23.12.2010 International Filing Date: 15.06.2010
IPC:
C07K 16/18 (2006.01), A61K 39/395 (2006.01), C07K 16/40 (2006.01)
Applicants: VIB VZW [BE/BE]; Rijvisschestraat 120 B-9052 Gent (BE) (For All Designated States Except US).
KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D [BE/BE]; Waaistraat 6, bus 5105 B-3000 Leuven (BE) (For All Designated States Except US).
DE STROOPER, Bart [BE/BE]; (BE) (For US Only).
ZHOU, Lujia [CN/BE]; (BE) (For US Only).
ANNAERT, Wim [BE/BE]; (BE) (For US Only)
Inventors: DE STROOPER, Bart; (BE).
ZHOU, Lujia; (BE).
ANNAERT, Wim; (BE)
Common
Representative:
VIB VZW; Rijvisschestraat 120 B-9052 Gent (BE)
Priority Data:
09162713.3 15.06.2009 EP
Title (EN) BACE1 INHIBITORY ANTIBODIES
(FR) ANTICORPS INHIBITEURS DE BACE1
Abstract: front page image
(EN)The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies which bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease.
(FR)La présente invention concerne des anticorps ayant une spécificité pour BACE1. Plus spécifiquement, l'invention concerne des anticorps monoclonaux qui se lient à BACE1 et sont capables d'inhiber l'activité de BACE1 et des procédés de production de ces anticorps. Lesdits anticorps peuvent être utilisés pour des applications de recherche et médicales. Des applications spécifiques comprennent l'utilisation d'anticorps spécifiques de BACE1 pour le traitement de la maladie d'Alzheimer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)